Schiff R - Search Results

1

Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.

Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG. Osborne CK, et al. Among authors: schiff r. Breast. 2005 Dec;14(6):458-65. doi: 10.1016/j.breast.2005.08.024. Epub 2005 Oct 19. Breast. 2005. PMID: 16236516 Review.

2

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW. Lavinsky RM, et al. Among authors: schiff r. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2920-5. doi: 10.1073/pnas.95.6.2920. Proc Natl Acad Sci U S A. 1998. PMID: 9501191 Free PMC article.

3

Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.

Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Hilsenbeck SG, et al. Among authors: schiff r. J Natl Cancer Inst. 1999 Mar 3;91(5):453-9. doi: 10.1093/jnci/91.5.453. J Natl Cancer Inst. 1999. PMID: 10070945

4

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Schiff R, et al. J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34. doi: 10.1093/jnci/92.23.1926. J Natl Cancer Inst. 2000. PMID: 11106684

5

Estrogen receptor: current understanding of its activation and modulation.

Osborne CK, Schiff R, Fuqua SA, Shou J. Osborne CK, et al. Among authors: schiff r. Clin Cancer Res. 2001 Dec;7(12 Suppl):4338s-4342s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916222 Review.

6

Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.

Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Liu Y, et al. Among authors: schiff r. Oncogene. 2002 Oct 31;21(50):7680-9. doi: 10.1038/sj.onc.1205883. Oncogene. 2002. PMID: 12400010

7

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Schiff R, Massarweh S, Shou J, Osborne CK. Schiff R, et al. Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S. Clin Cancer Res. 2003. PMID: 12538499 Review.

8

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Osborne CK, et al. Among authors: schiff r. J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. doi: 10.1093/jnci/95.5.353. J Natl Cancer Inst. 2003. PMID: 12618500

9

Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.

Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK. Morrison AJ, et al. Among authors: schiff r. Mol Endocrinol. 2003 Aug;17(8):1543-54. doi: 10.1210/me.2001-0144. Epub 2003 May 1. Mol Endocrinol. 2003. PMID: 12730327

10

Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters.

Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Fuqua SA, et al. Among authors: schiff r. Cancer Res. 2003 May 15;63(10):2434-9. Cancer Res. 2003. PMID: 12750263 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

370 results

Search Page